MedTrace Logo

A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

NCT07592910 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-18

No results posted yet for this study

Summary

The purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received enzalutamide, darolutamide, or apalutamide in the metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) setting but have not previously progressed on abiraterone.

Conditions

  • Metastatic Castrate Resistant Prostate Cancer (mCRPC)
  • Prostate Cancer (Adenocarcinoma)

Interventions

DRUG

Mevrometostat

875 mg oral tablet, taken twice daily with food

DRUG

Enzalutamide

160 mg oral capsule, taken once daily

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • Fred Hutchinson Cancer Center

    collaborator OTHER

  • Prostate Cancer Clinical Trials Consortium

    lead OTHER

Principal Investigators

  • Michael Schweizer, MD · University of Washington- Fred Hutch Cancer Center

  • Atish Choudhury, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2029-05-31
Completion
2029-08-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07592910 on ClinicalTrials.gov